The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Dolutegravir is one of the most effective and safest HIV medicines and is used by millions of adults and adolescents living ...